Atlas Trials

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Clinical trial NCT06106841 · TERMINATED

Trial details

NCT number
NCT06106841
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2023-10-05
Primary completion
2024-10-16
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.